Selux is on a mission to outsmart bacteria

With rapid phenotypic AST on all sample types

A Selux worker in the lab

Changing the status quo

Antibiotic susceptibility testing (AST) hasn’t seen true innovation in over 20+ years. All the while, bacteria have been evolving faster than science, creating resistance to lifesaving antibiotics.

According to the World Health Organization, antibiotic resistance is rising to dangerously high levels, becoming the next global health crisis. Selux is on a mission to combat AMR and preserve the lifesaving power of antibiotics for future generations.

Selux Analyzer

The global health crisis of antimicrobial resistant infections is a complex and multidimensional problem. The solution is the science and technology of Selux.

To preserve the lifesaving power of antibiotics we need faster diagnostic results, susceptibility testing on all sample types, testing against all commercially relevant antibiotics at one time, and a commitment to updated breakpoints.

Learn More

Our Solution

Comprehensive menu

Selux is confronting this global health crisis head-on by redefining speed in rapid AST, with our proprietary Next Generation Phenotyping (NGP) System. The Selux rapid NGP System starts with our proprietary 384-well panel. Never before has an AST system been able to break free of panel real estate constraints, until now. This unique design was carefully created to solve for the need of today’s health crisis of increasing antimicrobial resistance, while also preparing for the problems of the future.

Learn More

Rapid AST on all sample types

the Selux NGP system offers speed, high throughput, accuracy, and the most comprehensive bug / drug menus available. The power inside the Analyzer comes from utilizing our proprietary growth check assay, viability assay, and surface area assay – each helping to create a more precise analysis of cell health than traditional AST has been able to do before. Through our viability and surface area assays, we’re able to detect a cell dying without waiting for cell death – providing faster, comprehensive results.

Learn More

A patient in a hospital bed

Redefining patient care and antibiotic stewardship with rapid AST

Despite the importance of antimicrobial susceptibility testing (AST) to infectious diseases patient care, current AST systems either limit result speed, accuracy, or consistency. This forces an overreliance on broad-spectrum antibiotics and contributes to antimicrobial resistance. While multiple rapid AST technologies are under development, these are restricted to bloodstream infections so they cannot address the vast majority of hospitalized patients with other infections. The Selux NGP System offers same shift results, on all sample types.

Antibiotics

50%

Of antibiotics used in hospitals are either unnecessary or are prescribed incorrectly.

Selux Diagnostics

15

Every 15 minutes someone new dies of an antibiotic-resistant infection.

Super bug

2050

The year by which superbugs are expected to surpass cancer as a leading cause of death.

Let’s outsmart bacteria together.

Stay up to date with the latest breakpoint and the clinical impact of AST reporting.